Skip to main content

Table 1 Baseline characteristics of study participants

From: A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia

Variable Total group
(n = 144)
Arthritis
(n = 43)
No arthritis
(n = 101)
p value
 Time until end of follow-up (censoring or arthritis; months) 60 (1–60) 15 (0–60) 60 (30–60) <0.01
 Age (years)* 55 (11) 54 (11) 56 (12) NS
 Males (%) 23 28 21 NS
Disease activity     
 Tender joint count 53 0 (0–5) 0 (0–2) 0 (0–5) NS
 Visual analogue scale pain 29 (0–100) 35 (0–100) 26 (0–98) NS
 Use of NSAIDs (%) 29 35 26 NS
 ESR (mm/hour) 11 (0–34) 11 (0–34) 11 (1–31) NS
 CRP (mg/l) 2 (0–47) 2 (0–47) 3 (0–27) NS
 Fulfilment of 2010 ACR/EULAR classification criteria for RA (%) NA 95 0 NA
14-3-3η results     
 Level (ng/ml) 0.35 (0.03–20) 0.95 (0.12–20) 0.28 (0.03–20) <0.01
 ≥0.19 ng/ml (%) 71 86 64 <0.01
 ≥0.40 ng/ml (%) 45 58 40 0.04
 ≥0.80 ng/ml (%) 33 51 24 <0.01
RF results     
 Level (IU/ml) 38 (1–1192) 31 (1–383) 40 (1–1192) NS
 Positivity (%) 63 61 63 NS
ACPA results     
 Level (AU/ml) 108 (0–9860) 455 (0–8710) 59 (0–9860) <0.01
 Positivity (%) 65 95 53 <0.01
  1. Abbreviations: NS not significant, NSAIDs non-steroidal anti-inflammatory drugs, ESR erythrocyte sedimentation rate, CRP C-reactive protein, NA not applicable, RA rheumatoid arthritis, RF rheumatoid factor, IU/ml international units/ml, ACPA anti-citrullinated protein antibodies, AU/ml arbitrary units/ml, (p value ≥0.05)
  2. *Mean (SD), all other continuous variables mentioned as median (min-max)